Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMPT-1: Romiplostim for rapid platelet recovery after cord blood transplantation
jRCT2031180066Phase 1Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of romiplostim in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more, sponsored by Kyowa Kirin. Primary endpoint: Safety of romiplostim (AMG531). Started Apr 2019; status: active, not recruiting.
02
Drugs
romiplostim
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2031180066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031180066.